NCT07711418 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Status RECRUITING Phase PHASE3
NCT07690371 A Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis Status RECRUITING Phase PHASE3
NCT07660835 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants Aged 6 to 23 Months With Moderate-to Severe Atopic Dermatitis Status RECRUITING Phase PHASE2
NCT07502222 A Study to Evaluate the Efficacy and Safety of AK139 in Patients With Moderate-to-severe Atopic Dermatitis Status NOT_YET_RECRUITING Phase PHASE2
NCT07344051 A Phase II Study of QLS12010 Capsules in Adults With Moderate to Severe Atopic Dermatitis Status NOT_YET_RECRUITING Phase PHASE2
NCT07321951 A Study of SHR-1819 in Patients With Moderate-to-severe Atopic Dermatitis Status ACTIVE_NOT_RECRUITING Phase PHASE2
NCT07211542 A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis Status RECRUITING Phase PHASE2
NCT06934252 Phase 1a/1b Study of TRB-061 in Healthy Participants & Patients With Atopic Dermatitis Status RECRUITING Phase PHASE1
NCT06158490 A Study to Evaluate JYP0061 Tablets in Patients With Moderate-to-severe Atopic Dermatitis Status ENROLLING_BY_INVITATION Phase PHASE2
NCT05984784 A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of IMG-007 in Adults With Atopic Dermatitis (AD) Status TERMINATED Phase PHASE1/PHASE2
NCT05899816 A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) Status COMPLETED Phase PHASE3
NCT05590585 Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial Status COMPLETED Phase PHASE4
NCT05203380 Neuropsychologic Assessments of Dupilumab-Treated Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Status COMPLETED Phase N/A
NCT05186922 The Study of CM326 in Patients With Moderate-to-severe Atopic Dermatitis Status UNKNOWN Phase PHASE1/PHASE2
NCT05056779 Efficacy and Safety of Nemolizumab in Subjects With Moderate-to-Severe Atopic Dermatitis With Inadequate Response to or for Whom Cyclosporine A is Not Medically Advisable Status WITHDRAWN Phase PHASE3
NCT05017480 A Study to Evaluate the Efficacy and Safety of CBP-201 in Moderate to Severe Atopic Dermatitis in China Status COMPLETED Phase PHASE2
NCT04921345 Pharmacokinetics, Safety and Efficacy of Nemolizumab in Participants With Moderate-to-Severe Atopic Dermatitis Status COMPLETED Phase PHASE2
NCT04893941 Dose Escalation Trial of CM310 in Patients With Moderate-to-Severe Atopic Dermatitis (AD) Status COMPLETED Phase PHASE1/PHASE2